Emerging Horizons References

Page 26: Radiopharmaceutical Therapy: Emerging Horizons

References

1. Hertz B, Watabe T, Baum RP. Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics. Ann. Nucl. Med. 2022;36(12):1007-1009.
2. Strosberg JR, Caplin ME, Kunz PL, et al. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752–1763.
3. Strosberg J, Wolin E, Chasen B, et al. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. J. Clin. Oncol. 2018;36(25): 2578-2584.
4. Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet. 2021;397:797-804.
5. Sartor O, de Bono J, Chi KN, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2021; 385(12): 1091-1103.
6. Kiess AP, Hobbs RF, Bednarz B, et al. ASTRO’s Framework for Radiopharmaceutical Therapy Curriculum Development for Trainees. Int. J. Radiat. Oncol. Biol. Phys. 2022;113(4):7190726.
7. Udovicich C, Callahan J, Bressel M, et al. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma. Eur. Urol. Open Sci. 2022;44:60–68.
8. Thompson SM, Suman G, Torbenson MS, et al. PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Ga-PSMA-11 PET Using Cyclotron-Produced 68Ga. Hepatol. Commun. 2021;6(5):1172-1185.
9. Maclean J, Aldridge M, Bomanji J, et al. Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation. Pituitary. 2014;17(6):530–538.
10. Prasad RN, Perlow HK, Bovi J, et al. 68Ga-DOTATATE PET: The Future of Meningioma Treatment. Int. J. Radiat. Oncol. Biol. Phys. 2022;113(4):868–871.
11. Hasan H, Deek MP, Phillips R, et al. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). BMC Cancer. 2020;20(1):492.
12. King AP, Lin FI, Escorcia FE. Why bother with alpha particles? Eur. J. Nucl. Med. Mol. Imaging. 2021;49(1):7-17.
13. Feuerecker B, Tauber R, Knorr K, et al. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. Eur. Urol. 2021;79(3):343–350.
14. Delpassand ES, Tworowska I, Esfandiari R, et al. Targeted Alpha-Emitter Therapy With 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial. J. Nucl. Med. 2022;63(9):1326-1333.
15. Ballal S, Yadav MP, Tripathi M, et al. Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant ²²⁵ Ac-DOTATATE Targeted Alpha Therapy and Capecitabine: A Real-world Scenario Management Based Long-term Outcome Study. J. Nucl. Med. 2022:jnumed.122.264043.
16. Baum RP, Schuchardt C, Singh A, et al. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results. J. Nucl. Med. 2022;63:415–423.
17. Ferdinandus J, Costa PF, Kessler L, et al. Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients. J. Nucl. Med. 2022;63(5):727-734.
18. Kratochwil C, Flechsig P, Lindner T, et al. ⁶⁸ Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J. Nucl. Med. 2019;60(6):801–805.
19. Herrmann K, Schwaiger M, Lewis JS, et al. Radiotheranostics: a roadmap for future development. Lancet Oncol. 2020;21(3):e146–e156.
20. Duan H, Iagaru A, Aparici CM. Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging. Nanotheranostics. 2022;6(1):103–117.
21. Bodei L, Herrmann K, Schöder H, et al. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat. Rev. Clin. Oncol. 2022;19(8):534–550.

Authors:

Michael R. Folkert MD, PhD, is vice chair and chief of brachytherapy at Northwell Health Cancer Institute Radiation Medicine at the Center for Advanced Medicine in New York.

Ravi B. Patel, MD, PhD, is a radiation oncologist and an assistant professor at the University of Pittsburg Medical Center Hillman Cancer Center in Pennsylvania.

Kilian E. Salerno, MD, is a radiation oncologist and associate research physician in the Radiation Oncology Branch at the National Cancer Institute in Maryland.

Freddy E. Escorcia, MD, PhD, is a radiation oncologist and head of the Laboratory of Molecular Radiotherapy at the National Cancer Institute in Maryland.